Navigation Links
Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
Date:2/27/2012

HOBOKEN, N.J., Feb. 27, 2012  /PRNewswire/ -- Octapharma USA has submitted its Biological License Application (BLA) for octaplasLG® to the U.S. Food and Drug Administration (FDA) with the goal of expanding its U.S. product portfolio by the fourth quarter of 2012.

The FDA will evaluate the octaplasLG® BLA for an indication of managing preoperative or bleeding patients who require replacement of multiple plasma coagulation factors. The application also seeks to gain marketing approval for the substitution of intentionally removed plasma, such as plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP), a blood disorder that causes clot formation in small blood vessels. The product features solvent/detergent inactivation against enveloped viruses and immune neutralization against non-enveloped viruses.

"We look forward to bringing octaplasLG® to the U.S. medical community," said Octapharma USA President Flemming Nielsen. "This trusted therapy has been successfully used to treat patients for more than 15 years in Europe and over 30 countries worldwide."

Octapharma USA has started to lay the groundwork for the introduction of octaplasLG®, coordinating a physician advisory board meeting in late 2011 with leading treatment professionals in transfusion medicine, hematology and surgery.

About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for nearly 30 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.

Forward-looking statements
This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
2. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
3. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
4. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
5. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
6. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
7. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
8. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
9. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
10. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
11. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
(Date:5/24/2016)... -- ARANZ Medical  Ltd a specialist in ... been named the Coretex Hi-Tech Emerging Company of the Year ... Bruce Davey , CEO of ARANZ Medical says, "This ... to be recognised for the work we are doing to ... 35 countries around the world from Sub-Saharan Africa through to ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy Vending, LLC ... Joining the Grow Healthy Advisory Board team are Amanda Katchka, ... mission of our organization and bring talent, expertise and energy to ... continue to expand our footprint as the leader in healthy vending,” ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report ... on their access to trusted resources, both in face-to-face interactions and online. In “Heard, ... Color,” researchers concluded that the creative use of mobile digital devices can be an ...
(Date:5/24/2016)... ... May 24, 2016 , ... The number of ... people, or 10% over last year, according to data in the forthcoming AIS’s ... was comparatively stable, with a slight decrease in risk-based groups and a slight ...
(Date:5/24/2016)... ... ... Controlling and maintaining the home’s water heater just got infinitely easier, more ... Controller , a first-of-its-kind system that enables remote and convenient control of a water ... for HVAC systems, Aquanta gives users a much more efficient, versatile way to use ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Dream Builders Project, a ... other necessities to Eunime Orphanage in Tijuana, Mexico on Saturday, May 21st. The volunteers ... Peter Piper Pizza. , More than 15 volunteers traveled from Los Angeles to ...
Breaking Medicine News(10 mins):